Aurobindo Pharma growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+6.1%	+10.6%
EBITDA	+4.0%	+22.6%
Net Income	+0.6%	+22.0%
EPS (adj.)	+0.5%	+22.0%
Total Assets	+17.5%	+13.6%
Total Equity	+16.0%	+12.2%
Free Cash Flow	+72.4%	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AUROPHARMA₹1,644.80

Aurobindo Pharma Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA DRREDDY CIPLA FORTIS LUPIN ALKEM LAURUSLABS MANKINDMcap ₹95,530 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+6.1	+10.6
EBITDA	+4.0	+22.6
Net Income	+0.6	+22.0
EPS (adj.)	+0.5	+22.0
Total Assets	+17.5	+13.6
Total Equity	+16.0	+12.2
Free Cash Flow	+72.4	—

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.